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Abstract
Introduction. The aim of this study was to evaluate if women meeting criteria
for gestational diabetes mellitus (GDM) by the One Step test as per
International Association of the Diabetes and Pregnancy Study Groups
(IADPSG) criteria but not by other less strict criteria have adverse pregnancy
outcomes compared with GDM-negative controls. The primary outcome was
the incidence of macrosomia, defined as birthweight > 4000 g. Material and
methods. Electronic databases were searched from their inception until May
2017. All studies identifying pregnant women negative at the Two Step test,
but positive at the One Step test for IADPSG criteria were included. We
excluded studies that randomized women to the One Step vs. the Two Step
tests; studies that compared different criteria within the same screening
method; randomized studies comparing treatments for GDM; and studies
comparing incidence of GDM in women doing the One Step test vs. the Two
Step test. Results. Eight retrospective cohort studies, including 29 983 women,
were included. Five study groups and four control groups were identified. The
heterogeneity between the studies was high. Gestational hypertension,
preeclampsia and large for gestational age, as well as in some analyses cesarean
delivery, macrosomia and preterm birth, were significantly more frequent, and
small for gestational age in some analyses significantly less frequent, in women
GDM-positive by the One Step, but not the Two Step. Conclusion. Women
meeting criteria for GDM by IADPSG criteria but not by other less strict
criteria have an increased risk of adverse pregnancy outcomes such as
gestational hypertension, preeclampsia and large for gestational age, compared
with GDM-negative controls. Based on these findings, and evidence from other
studies that treatment decreases these adverse outcomes, we suggest screening
for GDM using the One Step IADPSG criteria.
Abbreviations: ACOG, American College of Obstetrics and Gynecologists; C&C,
Carpenter and Coustan; CDA, Canadian Diabetes Association; GCT, glucose
challenge test; GDM, gestational diabetes mellitus; IADPSG, International
Association of the Diabetes and Pregnancy Study Groups; LGA, large for
gestational age; NICE, National Institute for Health and Care Excellence;
NICU, neonatal intensive care unit; OGTT, oral glucose tolerance test; OR,
odds ratio; RCT, randomized controlled trial; SGA, small for gestational age;
WHO, World Health Organization.
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Introduction
Gestational diabetes mellitus (GDM) is defined as impaired
glucose tolerance first recognized during pregnancy (1).
GDM affects about 7–20% of pregnant women and this
value will probably increase in the future, due in particular
to maternal obesity (2). Prompt diagnosis and correct treat-
ment are essential, not only to decrease the risks of maternal
and neonatal morbidity and mortality, but also to reduce
health costs (1–6). In 2008, the hyperglycemia and adverse
pregnancy outcomes (HAPO) study showed strong, contin-
uous associations of maternal glucose levels below those
diagnostic for diabetes with increased birthweight (7).
Concerning diagnostic criteria, during the last decades
methods and cut-off values have changed several times
and complete international consensus about which crite-
ria to adopt has not been reached (1–6). The two most
common approaches to screen pregnant women for GDM
are the One Step and Two Step tests. Currently, the Inter-
national Association of the Diabetes and Pregnancy Study
Groups (IADPSG) (2), the World Health Organization
(WHO) (3), the International Federation of Obstetricians
and Gynecologists (4), the Canadian Diabetes Association
(CDA) (5) all recommend the 75 g 2 h One Step test,
while The American College of Obstetricians and Gyne-
cologists (ACOG) recommends the Two Step approach,
with first a 50-g 1-h test, and then, for those with abnor-
mal results, a 100-g 3-h test (6).
The One Step test usually diagnoses more women with
GDM than the Two Step test (8). It is unclear if these
‘extra’ women diagnosed with GDM by the One Step test
using IADPSG criteria but not by the Two Step test are
at increased risks for GDM complications compared with
women without GDM, and also, if they are, if treatment
for this ‘mild’ GDM is beneficial.
Our objective was to evaluate mainly if women meeting
criteria for GDM by IADPSG criteria, but not by other
less strict criteria, have adverse pregnancy outcomes com-
pared with GDM negative controls, and also if treatment
of these women has any potential maternal or perinatal
effects.
Material and methods
This is a review of the literature aimed at comparing
maternal and neonatal outcomes of women meeting crite-
ria for GDM by IADPSG criteria but not by other less
strict criteria, vs. GDM-negative controls. All studies were
identified through a review of the literature using
PubMed, Ovid, Google Scholar and Cochrane Review.
Databases were searched from their inception until May
2017. Search terms used were the following text words:
“diabetes”, “trial”, “screening”, “diagnosis”, “one-step”,
“two-step”, “guidelines”, “review”, “randomized” and
“clinical trial”. No restrictions for language or geographic
location were applied. In addition, the reference lists of
all identified articles were examined to identify studies
not captured by electronic searches. The electronic search
and the eligibility of the studies were independently
assessed by two authors (GS, CC). Differences were dis-
cussed with a third reviewer (VB).
We sought to identify in particular studies including
women meeting criteria for GDM based on the One Step
test by IADPSG criteria but not by other less strict crite-
ria, and reporting their outcomes compared with GDM-
negative controls. We also looked for any information
regarding GDM treatment of these (IADPSG-positive
only) women, to compare outcomes between those trea-
ted vs. those untreated.
We included studies, of any design, identifying preg-
nant women positive for IADPSG criteria, but negative at
the Two Step test as per ACOG Carpenter and Coustan
(C&C) criteria (6), WHO 1999 criteria (9), CDA criteria
(5), or National Institute for Health and Care Excellence
(NICE) Two Step criteria (Table 1) (10). We excluded
studies that randomized women to the One Step vs. the
Two Step tests; studies that compared different criteria
within the same screening method; randomized studies
comparing treatments for GDM; studies comparing
mainly incidence of GDM in women doing the One Step
test vs. other women doing the Two Step test; and studies
not reporting clinical outcomes.
Different criteria for GDM are shown in the Supple-
mentary material (Table S1).
We defined different groups of women within these
studies (Table 2). We defined the five study groups, all
positive for IADPSG criteria, but negative for other less
stringent GDM screening tests, as: (1) women who had at
least one positive value on the 2-h 75-g oral glucose toler-
ance test (OGTT) according to IADPSG criteria, but were
negative by C&C at the 100-g OGTT test (75-g IADPSG-
positive; 100-g C&C-negative); (2) women who had at
least one positive value on the 2-h 75-g OGTT according
to IADPSG criteria, but were negative by WHO criteria
(75-g IADPSG-positive; WHO-negative); (3) women who
had at least one positive value on the 2-h 75-g OGTT
Key message
Women meeting criteria for gestational diabetes mel-
litus by One Step IADPSG criteria, but not by other
less strict criteria, have an increased risk of adverse
pregnancy outcomes compared with gestational dia-
betes mellitus-negative controls.
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Table 1. Selected studies reporting outcomes of women meeting criteria for gestational diabetes mellitus based on the One Step test but not on
the Two Step test.
Author, year (origin)
(Ref) Study design
One Step positive
criteria (Study group) Control group
Two Step screening
criteria Primary outcome
Lapolla, 2011 (Italy)
(14)
Retrospective
cohort
100-g IADPSG
positive; C&C
negative
(Fasting 92–94 mg/
dL; 2 h 153–
154 mg/dL; not
treated)
[n = 112]
IADPSG negative
(Fasting <92 mg/dL;
1 h < 180 mg/dL;
2 h < 153 mg/dL)
[n = 1815]
50-g 1 h; if >140 mg/dL:
100-g 3 h GTT
2 abnormal of:
Fasting ≥95 mg/dL, or
1 h 180 mg/dl; 2 h
155 mg/dL;
3 h 140 mg/dLa
Perinatal
outcomes
Bodmer-Roy, 2012
(Canada) (15)
Retrospective
cohort
75-g IADPSG positive;
CDA negative
(Fasting 92–95 mg/
dL; 1 h 180–190
mg/dL; 2 h 153–
159 mg/dL; not
treated)
[n = 186]
GCT-negative
(50-g 1 h < 137 mg/dL)
[n = 186]
or
IADPSG-negative
(Fasting <92 mg/dL;
1 h < 180 mg/dL;
2 h < 153 mg/dL)
[n = 186]
50-g 1 h; if 137–184 mg/
dL: 75-g 2 h GTT
One abnormal of:
fasting ≥ 96 mg/dL; 1 h:
≥ 191 mg/dl: 2 h
≥ 160 mg/dLa
LGA >90th
percentile
Benhalima, 2013
(Belgium) (16)
Retrospective
cohort
100-g IADPSG
positive; C&C
negative
(Fasting 92–94 mg/
dL; 2 h 153–
154 mg/dL; not
treated)
[n = 160]
GCT-negative
(50-g 1 h < 140 mg/dL)
and
IADPSG-negative
(Fasting <92 mg/dL;
1 h < 180 mg/dL;
2 h < 153 mg/dL)
[n = 6345]
50 g 1 h; if ≥140 mg/dL:
100 g 3 h GTT
2 abnormal of:
Fasting ≥95 mg/dL, or
1 h 180 mg/dl; 2 h
155 mg/dL;
3 h 140 mg/dLa
Pregnancy
outcomes
Ethridge, 2014 (USA)
(17)
Retrospective
cohort
100-g IADPSG
positive; C&C
negative
(Fasting 92–94 mg/
dL; 2 h 153–
154 mg/dL; not
treated)
[n = 281]
GCT-negative
(50-g 1 h < 135 mg/dL)
[n = 6999]
or
IADPSG-negative
(Fasting <92 mg/dL;
1 h < 180 mg/dL;
2 h < 153 mg/dL)
[n = 772]
50-g 1 h; if ≥135 mg/dL:
100-g 3 h GTT
2 abnormal of:
Fasting ≥95 mg/dL, or
1 h 180 mg/dl; 2 h
155 mg/dL;
3 h 140 mg/dLa
Birthweight and
neonatal
outcomes
Liao, 2014 (China)
(18)
Retrospective
cohort
100-g IADPSG
positive; C&C
negative
(Fasting 92–94 mg/
dL; 2 h 153–
154 mg/dL; not
treated)
[n = 1314]
GCT-negative
(50-g 1 h < 140 mg/dL)
and
IADPSG-negative
(Fasting <92 mg/dL;
1 h < 180 mg/dL;
2 h < 153 mg/dL)
[n = 2662]
50 g 1 h; if ≥140 mg/dL:
100-g 3 h GTT
2 abnormal of:
Fasting ≥95 mg/dL, or
1 h 180 mg/dl; 2 h
155 mg/dL;
3 h 140 mg/dL
Maternal and
neonatal
outcomes
Mayo, 2015 (Canada)
(19)
Retrospective
cohort
75-g IADPSG positive;
CDA negative
(Fasting 92–95 mg/
dL; 1 h 180–190
mg/dL; 2 h 153–
159 mg/dL; not
treated)
[n = 155]
GCT-negative
(50-g 1 h < 140 mg/dL)
[n = 4183]
or
IADPSG negative
(Fasting <92 mg/dL;
1 h < 180 mg/dL;
2 h < 153 mg/dL)
[n = 526]
50-g 1 h;
if 140–184 mg/dL: 75-g
2 h GTT
One abnormal of:
fasting ≥95 mg/dL; 1 h:
≥191 mg/dl:
2 h ≥ 160 mg/dLa
Not stated
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according to IADPSG criteria, but were negative by CDA
criteria (75-g IADPSG-positive; CDA-negative); (4)
women who had at least one positive value on the 2-h
75-g OGTT according to IADPSG criteria, but were nega-
tive by NICE criteria (75-g IADPSG-positive; NICE-nega-
tive); (5) women who had at least one positive value on
the 100-g OGTT according to IADPSG criteria, but were
negative by C&C criteria at the 100-g OGTT test (100-g
IADPSG-positive; C&C-negative).
We defined the four control groups as: (1) women with
negative 50-g 1-h glucose challenge test results (GCT-nega-
tive); (2) women GDM-negative by IADPSG criteria on the
75-g One Step test (IADPSG-negative); (3) either (1) or (2),
together (GCT-negative or IADPSG-negative); (4) women
negative according to WHO criteria (WHO-negative).
We carefully extracted data from all selected papers
and we resolved disagreements by discussion.
We planned to compare maternal and neonatal out-
comes in study group (1) vs. any controls; study group (2)
vs. any controls; study group (3) vs. any controls; study
group (4) vs. any controls; study group (5) vs. any controls.
Among the five groups described above, we aimed to
compare several outcomes. We identified as our primary
outcome the incidence of macrosomia (defined as birth-
weight ≥ 4000 g).
Secondary outcomes were the following maternal and
neonatal outcomes: large-for-gestational-age (LGA) (birth-
weight > 90th centile), cesarean delivery, shoulder dystocia,
maternal gestational hypertension (i.e. blood pressure
≥ 140/90 mmHg occurring during pregnancy in previous
normotensive women), preeclampsia, admission to a
neonatal intensive care unit (NICU admission), prema-
ture delivery (defined as delivery before 37 weeks of
gestation), small-for-gestational-age (SGA) (birthweight
< 90th centile), clinical neonatal hypoglycemia, live
births and stillbirths.
The data analysis was completed independently by two
authors (CC, GS) using REVIEW MANAGER v. 5.3 (The Nor-
dic Cochrane Center, Cochrane Collaboration, 2014,
Copenhagen, Denmark). The completed analyses were
then compared, and any difference was resolved by dis-
cussion with a third reviewer (VB).
Data from each eligible study were extracted without
modification of original data onto custom-made data col-
lection forms. For continuous outcomes means  stan-
dard deviation were extracted and imported into REVIEW
MANAGER v. 5.3.
Meta-analysis was performed using the random effects
model of DerSimonian and Laird, to produce summary
treatment effects in terms of mean difference or odds
ratio (OR) with 95% confidence interval (95% CI).
Heterogeneity was measured using I-squared (Higgins I2).
Before data extraction, the review was registered with
the PROSPERO International Prospective Register of Sys-
tematic Reviews (CRD42017065654).
Results
We identified 73 studies on GDM screening comparison,
and these were assessed for eligibility (Figure 1). Sixty-two
Table 1. Continued
Author, year (origin)
(Ref) Study design
One Step positive
criteria (Study group) Control group
Two Step screening
criteria Primary outcome
Meek, 2015 (UK) (20) Retrospective
cohort
75-g IADPSG positive;
NICE negative
(Fasting 92–101 mg/
dL, 1 h ≥ 153 mg/
dL; not treated)
[n = 387]
IADPSG negative
(Fasting <92 mg/dL;
1 h < 180 mg/dL;
2 h < 153 mg/dL)
[n = 2406]
50-g 1 h;
if >138 mg/dL: 75-g 2 h
GTT
One abnormal of:
fasting ≥110/128 mg/dL;
2 h ≥ 140 mg/dLb
Delivery and
neonatal
outcomes
Tward, 2016
(Canada) (21)
Retrospective
cohort
75-g IADPSG positive;
CDA negative
(Fasting 92–95 mg/
dL; 1 h 180–
190 mg/dL; 2 h 153
–159 mg/dL; not
treated)
[n = 99]
GCT-negative
(50-g 1 h < 140 mg/dL
[n = 1021]
or
IADPSG negative
(Fasting <92 mg/dL;
1 h < 180 mg/dL;
2 h < 153 mg/dL)
[n = 184]
50-g 1 h; if >140 mg/dL:
75-g 2 h GTT
2 abnormal of: fasting
≥95 mg/dL; 1 h:
≥191 mg/dl:
2 h ≥ 160 mg/dL
Fetal grown in
twins
CDA, Canadian Diabetes Association; C&C, Carpenter and Coustan criteria; GCT, glucose challenge test; GTT, glucose tolerance test; IADPSG,
International Association of Diabetes Pregnancy Study Group; LGA, large for gestational age; NICE, National Institute for Health and Care Excel-
lence; WHO, World Health Organization.
a2008 Canadian Diabetes Association criteria (5).
bWHO 1999 criteria until 2007 (fasting 148 mg/dL), than modified WHO 1999 (fasting 130 mg/dL).
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were excluded, and therefore 11 studies reporting out-
comes of women meeting criteria for GDM based on
the One Step test but not on the Two Step test were
included. Deerochnawong et al. (11) and Mello et al. (12)
were excluded because while women were given both tests
(75 g and 100 g), the studies do not compare outcomes.
O’Sullivan et al. (13) was excluded because the study and
control groups contained overlapping patients. Therefore,
finally, eight studies (14–21) were included for final
analysis.
We found no study that compared 75-g IADPSG-posi-
tive, 100-g C&C-negative women to any of the possible
controls. We found no study that compared 75-g
IADPSG-positive, WHO-negative women to any of the
possible controls, as O’Sullivan et al. (13) had to be
excluded. Instead we recognized eight studies that identi-
fied women negative at the 75-g CDA, 75-g NICE test, or
100-g C&C tests, but positive for milder GDM criteria
(either 75-g or 100-g IADPSG criteria) (14–21).
Three of the included studies considered women posi-
tive at 75-g IADPSG criteria, but CDA criteria negative
(15,19,21). One study included women meeting criteria
for GDM based on 75-g IADPSG criteria, but NICE crite-
ria negative (20). Four of the included studies had as
study group women positive for 100-g IADPSG criteria,
but negative on C&C criteria (14,16–18).
Regarding control groups, two of the included studies
considered women with negative GCT, six studies
included as controls women who were IADPSG-negative,
four studies considered GCT-negative or IADPSG-nega-
tive, and no studies had as control group women who
were WHO-negative (Table 2).
Supplementary material (Table S1) reports the recom-
mendations of guidelines used in the eight studies that
we included in our analysis. Table 1 shows the character-
istics of the included studies. All eight studies were retro-
spective cohort studies. For the GCT-negative controls,
the cut-offs varied between 135 and 140 mg/dL. The
study by Tward et al. includes only twin pregnancies, so
fetal outcomes are referred to both twins. No study trea-
ted for GDM either the study or control groups.
In the three studies of women positive at 75-g IADPSG
criteria, but CDA criteria negative, gestational hyperten-
sion [17/341 (5.0%) vs. 112/5081 (2.2%); OR 2.55, 95%
CI 1.41–4.61], preeclampsia [16/341 (4.7%) vs. 46/5081
(0.9%); OR 2.75, 95% CI 1.38–5.45], hypertensive com-
plications [27/254 (10.6%) vs. 278/5914 (4.7%); OR 1.81,
95% CI 1.19–2.76], cesarean delivery [205/440 (46.6%)
vs. 2180/6286 (34.7%); OR 1.68, 95% CI 1.34–2.11] and
LGA babies [38/341 (11.1%) vs. 411/5081 (8.1%); OR
1.69, 95% CI 1.15–2.48] were significantly more common;
our main outcome, macrosomia, was more frequent in
women positive at 75-g IADPSG criteria and CDA criteria
negative, but did not reach a statistically significant differ-
ence [39/341 (11.4%) vs. 475/5081 (9.3%); OR 1.32, 95%
CI 0.90–1.92] (Tables 3 and 4).
In the one study of women positive on 75-g IADPSG
criteria, but NICE criteria negative, macrosomia [112/387
(28.9%) vs. 403/2406 (16.8%); OR 2.02, 95% CI 1.59–
2.58], LGA babies [115/387 (29.7%) vs. 406/2406
(16.9%); OR 2.08, 95% CI 1.63–2.65] and preeclampsia
[39/387 (10.1%) vs. 174/2406 (7.2%); OR 1.44, 95% CI
1.00–2.07], were significantly more common. Other out-
comes did not reach a statistically significant difference
(Table 5 and 6).
In the four studies of women positive for 100-g
IADPSG criteria, but negative on C&C criteria, preeclamp-
sia [27/1474 (1.8%) vs. 66/9011 (0.7%); OR 1.82, 95% CI
1.09–3.05], gestational hypertension [75/1867 (4.0%) vs.
825/1859 (4.4%); OR 1.58, 95% CI 1.21–2.07], cesarean
delivery [180/553 (32.5%) vs. 3860/15931 (24.2%); OR
1.46, 95% CI 1.21–1.75], LGA babies [157/1867 (8.4%) vs.
1688/18597 (9.1%); OR 1.36, 95% CI 1.13–1.64], preterm
birth [113/1474 (7.7%) vs. 1799/9011 (20.0%); OR 1.67,
95% CI 1.33–2.10], NICU admission [116/1755 (6.6%) vs.
1318/16782 (7.9%); OR 1.32, 95% CI 1.06–1.64], and
neonatal hypoglycemia [18/1314 (1.3%) vs. 18/2666
(0.7%); OR 2.04, 95% CI 1.06–3.94] were significantly
more common; whereas SGA babies [13/243 (5.3%) vs.
Table 2. Study groups and Control groups definitionsa.
Study groups (Ref) Control groups
1) 75-g IADPSG-positive; 100 g C&C-negative: no studies 1) GCT-negative: 2 studies (16,18)
2) 75-g IADPSG-positive; WHO-negative: no studies 2) IADPSG-negative: 2 studies (14,20)
3) 75-g IADPSG-positive; CDA-negative: 3 studies (15,19,21) 3) GCT-negative or IADPSG-negative: 4 studies (15,17,19,21)
4) 75-g IADPSG-positive; NICE-negative: 1 study (20) 4) WHO-negative: no studies
5) 100-g IADPSG-positive; C&C-negative: 4 studies (14,16–18)
CDA, Canadian Diabetes Association; C&C, Carpenter and Coustan criteria; GCT, glucose challenge test; IADPSG, International Association of Dia-
betes Pregnancy Study Group; NICE, National Institute for Health and Care Excellence; WHO, World Health Organization.
aFor details of criteria, see Supplementary material (Table S1).
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93 records
screened
20 records
excluded
93 records after duplicates
removed
100 records
identified through
database
searching
n = 33 studies
comparing
different criteria
within the same
screening method
n = 14 randomized
studies comparing
different
treatments for
GDM
n = 10 studies
comparing mainly
incidence of GDM
in women doing
the One Step test
vs. other
women doing the
Two Step test
n = 3 studies that
randomized
women to the One
Step vs. the
Two Step tests
n = 2 without
clinical outcomes
73 full-text articles
assessed for 
eligibility
62 full-text articles
excluded:
11 studies
included in
qualitative
synthesis
8 studies included
in quantitative
synthesis
(meta-analysis)
n = 2 studies in which while
women were give both tests
(75 g and 100 g), the studies
do not campare outcomes
n = 1 study excluded because
study and control groups have
overlapping patients
Figure 1. Flow diagram of studies identified in the systematic review. T
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106/4481 (2.4%); OR 0.49, 95% CI 0.27–0.89] were signifi-
cantly less common. Our main outcome, macrosomia, was
more frequent in women positive at 100-g IADPSG criteria
and C&C-criteria negative, but did not reach a statistically
significant difference [75/1867 (4.0%) vs. 1153/18597
(6.2%); OR 1.20, 95% CI 0.93–1.55] (Table 7 and 8).
We identified no study that evaluated whether treat-
ment of women meeting criteria for GDM by IADPSG
criteria but not by other less strict criteria has an
effect on adverse pregnancy outcomes compared with no
treatment.
Discussion
This meta-analysis showed that women meeting criteria
for GDM by IADPSG criteria but not by other less strict
criteria have an increased risk of adverse pregnancy out-
comes such as gestational hypertension, preeclampsia and
LGA, compared with GDM-negative controls. These find-
ings are limited by the risk of bias of the included studies
and by the high heterogeneity within the studies.
When analyzing outcomes of all study groups with
respect to all control groups for maternal outcomes, we
found that gestational hypertension and preeclampsia
were consistently significantly more common in women
who were GDM positive by more strict IADPSG criteria
compared with GDM-negative controls, and cesarean
delivery was also more common, with two of three anal-
yses being statistically significant (Table 9). When ana-
lyzing outcomes of all study groups with respect to all
control groups for neonatal outcomes, we found that
LGA was consistently significantly more common in
women who were GDM positive by more strict IADPSG
criteria compared with GDM-negative controls, and
macrosomia and preterm birth were also more common,
with only one of the analyses being statistically signifi-
cant; SGA was less common in the two available analy-
ses, with one of these being statistically significant
(Table 10).
Despite continuing controversy over whether the One
Step test or the Two Step tests should be used for GDM
screening, we identified no study that evaluated if treat-
ment of women meeting criteria for GDM by IADPSG
criteria (One Step test) but not by other less strict criteria
has an effect on adverse pregnancy outcomes compared
with no treatment. Moreover, none of the included stud-
ies treated for GDM the study group with milder disease
(positive for IADPSG criteria, but negative for less strin-
gent criteria).
We are not aware of such a comprehensive systematic
review on maternal and neonatal outcomes in women
meeting criteria for GDM by IADPSG criteria but not
by other less strict criteria compared with GDM-Ta
b
le
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negative controls. The first issue in deciding whether to
use the One Step or the Two Step for GDM screening
and diagnosis is to ascertain if women diagnosed with
the One Step, but not the Two Step, are at increased
risk for complications compared with GDM-negative
controls. The fact that for the first time a comprehen-
sive review finds that gestational hypertension,
preeclampsia and LGA, as well as possibly cesarean
delivery, macrosomia and preterm birth, are more fre-
quent, and SGA possibly less frequent, in women diag-
nosed with GDM by the One Step, but not the Two
Step, is an important strength of our study. Moreover,
none of the studies treated women identified with the
One Step, but not the Two Step, so the results are not
affected by GDM therapy.
There are also several limitations to our study. In each
study group we identified only a few studies, and, impor-
tantly, no one was a randomized controlled trial (RCT).
We also found a large variety of different criteria
(IADPSG, WHO, NICE, CDA, C&C) for screening for
GDM used in the literature, as can be seen in the Supple-
mentary material (Table S1). Moreover, some studies
used 75-g (IADPSG) criteria in women who instead had
the 100-g glucose load. Furthermore, in study group 5
[women who had at least one positive value on the 100-g
OGTT according to IADPSG criteria, but were negative
by C&C criteria at the 100-g OGTT test (100-g IADPSG-
positive; C&C-negative)] the authors applied IADPSG cri-
teria in women who underwent 100-g OGTT rather than
75-g OGTT.
To compare the One Step test to the Two Step tests for
GDM screening and diagnosis, several possible study
designs have been evaluated in the literature.
Only one RCT has been published in which women
underwent both the One Step and the Two Step test.
Weiss et al. concluded that, although in metabolically
healthy women both different GDM screening approaches
lead to statistically different blood glucose levels at 1 and
2 h, in GDM 1-h glucose levels do not differ after a 75-g
or 100-g load, and this is due to elevated insulin resis-
tance shown by a low insulin/glucose quotient at 1 h. For
comparison of tests in GDM only, 2-h values must be
adjusted by 16 mg/dL after different loading (22).
Three RCTs comparing the One Step with the Two
Step approaches have been published (7,8,23–28). The
meta-analysis of the three RCTs included 2,333 women.
No significant difference in the incidence of GDM was
found comparing the One Step vs. the Two Step
approaches (8.4% vs. 4.3%; RR 1.64, 95% CI 0.77 to
3.48). Women screened with the One Step approach had
a significantly lower risk of preterm birth (PTB) (3.7%
vs. 7.6%; RR 0.49, 95% CI 0.27 to 0.88), cesarean delivery
(16.3% vs. 22.0%; RR 0.74, 95% CI 0.56 to 0.99),
macrosomia (2.9% vs. 6.9%; RR 0.43, 95% CI 0.22 to
0.82), neonatal hypoglycemia (1.7% vs. 4.5%; RR 0.38,
95% CI 0.16 to 0.90), and admission to neonatal inten-
sive care unit (NICU) (4.4% vs. 9.0%; RR 0.49, 95% CI
0.29 to 0.84), compared to those randomized to screening
with the Two Step approach (29).
Several prospective non-RCTs or retrospective studies
comparing the incidence of GDM and/or outcomes
between the One Step and Two Step methods have also
been published (30–37). Polled data of these studies show
that GDM-positive women at One Step test, when treated,
have better maternal and neonatal outcomes, compared
with treated women GDM positive at Two Step test.
In summary, compared with GDM-negative women,
women positive at the One Step test by IADPSG criteria
but negative at the Two Step test are at increased risk for
gestational hypertension, preeclampsia and LGA, as well
as possibly cesarean delivery, macrosomia and preterm
birth, while possibly being at decreased risk for SGA.
Given the fact that the One Step approach has been often
associated in RCTs (7,8,28,38,39) with better maternal
and perinatal outcomes, including lower risk of preterm
birth, cesarean delivery, macrosomia, neonatal hypo-
glycemia, admission to NICU and lower mean birthweight,
compared with the Two Step approach, consideration
should be given to universal adoption of the One Step
approach using the IADPSG criteria for GDM screening
and diagnosis.
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